Peptides: Tesamorelin — The Only FDA-Approved GH Peptide for Body Composition
Falutz et al. 2007 (PMID 18057338): tesamorelin 2mg/day × 26 weeks reduced visceral adipose tissue by 15.2% vs placebo in HIV-associated lipodystrophy Phase 3 trial.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | A | grade | Tesamorelin — FDA-approved indication based on Phase 3 RCTs; multiple trials; Grade B for off-label general use |
| FDA Approval Year | 2010 | year | Approved as Egrifta; indication: HIV-associated lipodystrophy (visceral fat accumulation) |
| Visceral Fat Reduction (Phase 3) | 15.2 | % decrease in VAT | Falutz 2007 Phase 3 (PMID 18057338): vs placebo over 26 weeks; visceral adipose tissue by DXA/CT |
| IGF-1 Increase | 40–50 | % over baseline | Clinical trial data; consistent across Phase 2 and Phase 3; normalized to age-matched reference ranges |
| Approved Dose | 2 | mg/day subcutaneous | Once-daily subcutaneous injection; must be refrigerated; compounding sources available off-label |
| Half-Life | 26 | minutes | Short half-life requires daily injection; unlike CJC-1295 DAC which has multi-day half-life |
| Structural Modification | Trans-3-hexenoic acid | N-terminal modification | Trans-3-hexenoic acid group added to GHRH 1-44 analogue; improves stability vs native GHRH |
The Only FDA-Approved GH Peptide for Body Composition
Tesamorelin occupies a unique regulatory position: it is the only growth hormone-releasing peptide with FDA approval for a body composition indication. Approved in 2010 under the brand name Egrifta, its approved use is the treatment of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy caused by antiretroviral therapy.
This approval is based on Phase 3 RCT evidence — not off-label extrapolation, not preclinical data, not anecdote. That regulatory track record makes tesamorelin the benchmark against which all other GH peptides should be measured for body composition claims.
Structure and Mechanism
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH 1-44) modified at the N-terminus with a trans-3-hexenoic acid group. This modification improves stability against plasma proteolysis while preserving full GHRH receptor binding.
Mechanism:
- Binds GHRH receptor on pituitary somatotroph cells
- Stimulates pulsatile GH release (physiological pattern, unlike exogenous HGH bolus)
- GH elevation → increased hepatic IGF-1 secretion (~40–50% increase from baseline)
- GH acts directly on visceral adipocytes → lipolysis, particularly in abdominal fat depots
The short half-life (~26 minutes) means tesamorelin is cleared rapidly and GH stimulation occurs in discrete pulses following injection — mimicking the natural pattern more closely than long-acting analogues.
Clinical Trial Data
| Trial | Indication | n | Dose | Duration | Primary Outcome | Result |
|---|---|---|---|---|---|---|
| Falutz 2007 Phase 2 (PMID 18057338) | HIV lipodystrophy | 61 | 2mg/day subcut | 12 weeks | VAT reduction | Significant VAT reduction; IGF-1 +40% |
| Falutz 2007 Phase 3 (PMID 18057338) | HIV lipodystrophy | 412 | 2mg/day subcut | 26 weeks | VAT by CT scan | 15.2% VAT reduction vs placebo (p<0.001) |
| Dhaliwal 2011 extension | HIV lipodystrophy | ~270 | 2mg/day subcut | 52 weeks | Sustained VAT reduction | Maintained; no new safety signals |
| Falutz 2012 long-term (PMID 22739392) | HIV lipodystrophy | ~400 | 2mg/day subcut | 26–52 weeks | Safety + body comp | Maintained efficacy; no concerning glucose changes |
| Off-label general population | Visceral fat / body comp | Limited case series | 2mg/day | Variable | VAT reduction | Directionally consistent; no Phase 3 |
The Phase 3 findings are robust. In the pivotal trial (n=412), tesamorelin 2mg/day reduced visceral adipose tissue by 15.2% compared to placebo — a meaningful reduction in abdominal fat measured by CT scan, the gold standard for VAT quantification. IGF-1 increased by approximately 40–50% from baseline, consistent with other GH secretagogues at comparable doses.
Side Effects
Joint pain and myalgia (GH-related) are the most common side effects, reported in 10–15% of trial participants. Water retention occurs but is less pronounced than with full HGH. Injection site reactions are typical for any subcutaneous daily injection protocol. Glucose monitoring is recommended, though diabetogenic effects were minimal in the approved 2mg dose.
Legal and Regulatory Status
| Jurisdiction | Status | Schedule | Notes |
|---|---|---|---|
| USA | Prescription only | Schedule Rx | FDA-approved as Egrifta; compounding versions exist for off-label use |
| UK | No licensed product | — | No equivalent MHRA-approved product; no prescription pathway via this name |
| Australia | Schedule 4 | Prescription required | TGA scheduling; no TGA-approved product; off-label prescription possible |
| Canada | Schedule F | Prescription required | Health Canada approved for HIV lipodystrophy indication |
| EU | Not approved | — | No EMA marketing authorization; some EU countries allow off-label physician prescribing |
Off-Label Context
Tesamorelin’s mechanism is not HIV-specific. Visceral fat accumulation is a broad metabolic problem in the general population, and the physiological mechanism — GH stimulation → visceral lipolysis — operates identically regardless of HIV status. This has led to off-label use in the general population through compounding pharmacies.
The evidence extrapolation is reasonable at a mechanistic level, but the absence of large RCTs in non-HIV populations means clinicians and patients are operating on Grade B evidence for general use. The efficacy and side-effect profile may differ in patients not on antiretroviral therapy.
Related Pages
Sources
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PMID 18057338
- Falutz J et al. Long-term safety and effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. AIDS. 2012;26(14):1691-8. PMID 22739392
Frequently Asked Questions
What makes tesamorelin different from other GHRH analogues like CJC-1295?
Tesamorelin is a modified GHRH analogue (trans-3-hexenoic acid at the N-terminus of GHRH 1-44) with FDA approval for a specific body composition indication. CJC-1295 is another GHRH analogue but lacks any FDA-approved indication and has no Phase 3 human trial data. Tesamorelin's 26-minute half-life requires daily dosing; CJC-1295 with DAC has a multi-day half-life. Only tesamorelin has completed the formal pharmaceutical trial process.
Can people without HIV use tesamorelin for fat loss?
There is no FDA-approved indication for tesamorelin outside of HIV-associated lipodystrophy. Off-label use in the general population is pharmacologically plausible — the mechanism of visceral fat reduction via GH stimulation is not HIV-specific — but there are no large RCTs in the general population. Evidence for off-label use is Grade B at best. Compounding pharmacies produce tesamorelin for off-label prescribing where physicians choose to do so.
Why was a GHRH analogue developed for HIV patients specifically?
HIV antiretroviral therapy (ART), particularly older protease inhibitors, causes lipodystrophy syndrome: visceral fat accumulation, peripheral fat loss, and dyslipidemia. These are metabolic effects of the ART drugs themselves. Full recombinant HGH was tested first but caused significant side effects (glucose intolerance, joint pain) at doses needed for fat loss. Tesamorelin achieves GH stimulation through physiological pulsatile release, producing visceral fat reduction with fewer metabolic side effects.
What does the 2012 long-term safety study show?
Falutz et al. 2012 (PMID 22739392) followed patients for up to 52 weeks on tesamorelin 2mg/day. Visceral fat reduction was maintained through the extension period. The compound remained well-tolerated with no new safety signals. Glucose parameters were monitored closely and did not show significant diabetogenic effects at this dose, distinguishing it favorably from full HGH at growth-promoting doses.